Viruses for tumor therapy

Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

Natural killer cells: the secret weapon in dendritic cell vaccination strategies

Novel approaches and mechanisms of immunotherapy for glioblastoma

Phase I dendritic cell p53 peptide vaccine for head and neck cancer

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

DNA fragmentation and caspase-independent programmed cell death by modulated electrohyperthermia

Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response